Abstract: The present invention relates to a crosslinkable polymer formulation comprising a polymer which contains a silazane repeating unit; and a specific boron Lewis acid curing catalyst, wherein the curing catalyst catalyzes the crosslinking of the polymer to obtain a crosslinked polymer composition. The crosslinked polymer composition is particularly suitable as a technical coating for industrial or household applications.

Abstract: Disclosed are liquid-crystalline media (LC media) comprising a low-molecular-weight component and a polymerisable component. The polymerisable component contains self-aligning, polymerisable meso-gens (polymerisable self-alignment additives) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). Disclosed are also LC displays having homeotropic alignment of the LC medium without alignment layers. Further disclosed are the structures for polymerisable self-alignment additives.

Abstract: The present invention relates to organic electroluminescent devices comprising metal complexes of the formula (1), and to metal complexes for use in organic electroluminescent devices. Depending on the metal used, the metal complexes are useful as emitters, as matrix materials, as hole-blocking materials, as electron-transport materials, and in other functions in the OLED. Organic electroluminescent devices comprising the metal chelate complexes described herein result in significant improvements in the organic electroluminescent device, in particular with respect to the lifetime, the efficiency and the stability to heating, particularly in green- and blue-phosphorescent electroluminescent devices.

Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: A liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula T in which denotes and the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the compounds of formula T and their use for the improvement of the transmission and/or response times of a liquid-crystalline medium which contains one or more additional mesogenic compounds.

Abstract: The present invention relates to an optical medium (100) and an optical device (200) comprising an optical medium (100). The present invention further relates to a use of the optical medium (100) in an optical device (200). The invention further more relates to method for preparing the optical medium (100) and method for preparing the optical device (200).

Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, Y, Z, R1, R7A, R7B and R8 are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets Clostridium difficile (C. difficile) toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with a treatment that 5 targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.

Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.

Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.

Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.

Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.

Abstract: The present invention relates to novel phosphor mixtures and to a light-emitting device which comprises at least one of the novel phosphor mixtures. The phosphor mixtures can be used in phosphor-converted LEDs with a semiconductor that emits in the violet spectral region. The present invention furthermore relates to a lighting system which may comprise the light-emitting devices according to the invention, and to a dynamic lighting system. The present invention furthermore relates to a process for the preparation of the phosphor mixtures according to the invention and to the use thereof in light-emitting devices for use in general lighting and/or in specialty lighting.

Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

Abstract: The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Abstract: The present invention relates to a method, a medium and a kit for the enrichment and detection of Listeria species, especially Listeria monocytogenes. The medium is an enrichment medium comprising C12 to C16 fatty acids and/or derivatives thereof.

Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.

Abstract: The present invention relates to a method of detecting a microorganism, in particular Staphylococcus aureus, in a sample, comprising the steps of a) incubating the sample with a slow off-rate modified aptamer (SOMAmer) comprising a fluorescent label, b) optionally washing the sample, c) analyzing the sample by a fluorescence-based detection method. The invention further relates to a slow off-rate modified aptamer comprising a fluorescent label, wherein the SOMAmer comprises a nucleotide sequence specific for Staphylococcus aureus, its use for detecting Staphylococcus aureus cells in a sample, and to a microarray or biosensor and a kit comprising at least one of such SOMAmers comprising a fluorescent label.

Abstract: The present invention is directed to Compounds of Formula (I) and salts thereof, wherein R1, R2, R3 and R4 are defined above herein. The present invention is also directed to uses of the compounds of Formula (I) to add phosphoramidate groups onto organic alcohols.